Future Directions and Research Priorities in BTKi Treatment Approaches

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) may include issues related to access, cost, and patient adherence, and highlight the need for ongoing research and collaboration to optimize BTKi use and improve patient outcomes in both diseases.

EP: 1.Emerging BTKi Combinations in CLL: A New Frontier of Treatment Options

EP: 2.Clinical Implications and Unmet Needs in CLL BTKi Therapies

EP: 3.Navigating New BTKi Treatment Strategies in Mantle Cell Lymphoma

EP: 4.Integrating Emerging BTKi Therapies Into Current Treatment Guidelines

Now Viewing

EP: 5.Future Directions and Research Priorities in BTKi Treatment Approaches

Video content above is prompted by the following:

1. What challenges do you anticipate in the implementation of these emerging BTKi regimens for treatment-naive patients with CLL or MCL, and how might these challenges be addressed?
2. What are you most looking forward to seeing in the use of BTK inhibitors, and what are some key areas where you think further research and collaboration are needed to continue improving patient outcomes?

Related Videos